The Prx6 and Trx 1 overexpression had been reported to activate AKT1 or/and EKR1/2 signaling pathways in lung cancer or ischemia [40], [41], we now showed in reverse that AL-1-activated AKT1 and ERK1/2 could increase the expression of Prx5 and Trx1 (Fig. 6E). Here, MAPK3 is linked to lung cancer.